Synergistic antiangiogenic effects of stathmin inhibition and taxol exposure

Molecular Cancer Research

Volumn 5, Issue 8, 2007, Pages 773-782

  Mistry, Sucharita J ^a   Bank, Alexander ^a   Atweh, George F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; PACLITAXEL; RIBOZYME; STATHMIN;

ADENOVIRUS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MICROTUBULE; PRIORITY JOURNAL;

ADENOVIRIDAE; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELLS, CULTURED; COMBINED MODALITY THERAPY; ENDOTHELIUM, VASCULAR; HUMANS; MICROTUBULES; NEOVASCULARIZATION, PHYSIOLOGIC; PACLITAXEL; RNA, CATALYTIC; STATHMIN; UMBILICAL VEINS;

ADENOVIRIDAE; EUKARYOTA;

EID: 34548098053     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0290     Document Type: Article

References (37)

1. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64.
2. Ingber D, Prusty D, Zhengqi S, Betensky H, Wang N. Cell shape, cytoskeletal mechanics and cell cycle control in angiogenesis. J Biomech 1995;28:1471-84.
3. Hayot C, Farinelle S, De Decker R, et al. In vitro pharmocological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol 2002;21:417-25.
4. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
5. Wang J, Luo P, Lesniewski R, Henkin J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs 2003;14:13-9.
6. Hanash S, Strahler JR, Kuick R, Chu EHY, Nichols D. Identification of a polypeptide associated with the malignant phenotype in acute leukemia. J Biol Chem 1988;263:12813-5.
7. Friedrich B, Gronberg H, Landstrom M, Gullberg M, Bergh A. Differentiation-stage specific expression of oncoprotein 18 in human and rat prostatic adenocarcinoma. Prostate 1995;27:102-9.
8. Brattsand G. Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors. Br J Cancer 2000;83:311-8.
9. Mistry SJ, Atweh GF. Role of stathmin in the regulation of the mitotic spindle: potential applications in cancer therapy. Mt Sinai J Med 2002;69:299-304.
10. Belmont L, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996;84:623-31.
11. Marklund U, Larsson N, Gradin HM, Brattsand G, Gullberg M. Oncoprotein 18 is a phosphorylation-responsive regulator of microtubule dynamics. EMBO J 1996;15:5290-8.
12. Mistry SJ, Atweh GF. Stathmin inhibition enhances okadaic acid-induced mitotic arrest: a potential role for stathmin in mitotic exit. J Biol Chem 2001;276:31209-15.
13. Mistry SJ, Li HC, Atweh GF. Role for protein phosphatases in the cell-cycle - regulated phosphorylation of stathmin. Biochem J 1998;334:23-9.
14. Luo X, Mookerjee B, Ferrari A, Mistry S, Atweh GF. Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2kinase. J Biol Chem 1994;269:10312-8.
15. Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of stathmin inhibition on the mitotic spindle. J Cell Sci 2001;114:909-16.
16. Mistry SJ, Atweh GF. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer. Mol Cancer Ther 2006;5:3248-57.
17. Mistry SJ, Benham CJ, Atweh GF. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle. Antisense Nucleic Acid Drug Dev 2001;11:41-9.
18. Mistry SJ, Bank A, Atweh GF. Targeting stathmin in prostate cancer. Mol Cancer Ther 2005;4:1821-9.
19. Kubota Y, Kleinman HK, Martin GR, Lawley TJ. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol 1988;107:1589-98.
20. Chou T, Talalay P. Quantitative analysis of dose effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
21. Howell B, Deacon H, Cassimeris L. Decreasing oncoprotein 18/stathmin levels reduces microtubule catastrophes and increases microtubule polymer in vivo. J Cell Sci 1999;112:3713-22.
22. Parness J, Horwitz SB. Taxol binds to polymerized tubulin in vitro. J Biol Chem 1981;91:479-87.
23. Baldassarre G, Belletti B, Nicoloso MS, et al. p27(Kip 1) stathmin interaction influences sarcoma cell migration and invasion. Cancer Cell 2005;7:51-63.
24. Giampietro C, Luzzati F, Gambarotta G, et al. Stathmin expression modulates migratory properties of GN-11 neurons in vitro. Endocrinology 2005;146:1825-34.
25. Niethammer P, Bastiaens P, Karsenti E. Stathmin tubulin interaction gradients in motile and mitotic cells. Science 2004;303:1862-6.
26. Ueda M, Graf R, MacWilliams HK, Schliwa M, Euteneuer U. Centrosome positioning and directionality of cell movements. Proc Natl Acad Sci U S A 1997;94:9674-8.
27. Gotlieb AI, May LM, Subramanyam L, Kalnins VI. Distribution of microtubule organizing centers in migrating sheets of endothelial cells. J Cell Biol 1981;91:589-94.
28. Gundersen G, Bulinski JC. Selective stabilzation of microtubules oriented toward the direction of cell migration. Proc Natl Acad Sci U SA 1988;85:5946-50.
29. Grant D, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003;104:121-9.
30. Miyashita H, Kanemura M, Abe M, Sato Y. Vascular endothelial zinc finger 1 is involved in the regulation of angiogenesis: possible contribution of stathmin/Op18 as a downstream target gene. Arterioscler Thromb Vasc Biol 2004;24:878-84.
31. Kerr D. Targeting angiogenesis in cancer: clinical development of bevacizumab. Nat Clin Pract Oncol 2004;1:39-43.
32. Kindler H. Friberg G, Singh DA, et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005;23:8033-40.
33. Jeha S, Luo XN, Beran M, Kantarjian H, Atweh GF. Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells. Cancer Res 1996;56:1445-50.
34. Graham F, Prevec L. Methods for construction of adenovirus vectors. Mol Biotechnol 1995;3:207-20.
35. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor (NY): Cold Spring Harbor Laboratory; 1989.
36. Zhu X, Kozarsky K, Strahler JR, et al. Molecular cloning of a novel human leukemia-associated gene. Evidence of conservation in animal species. J Biol Chem 1989;264:14556-60.
37. Reimer CL, Agata N, Tamman JG, et al. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res 2002;62:789-95.